Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Nathan, Paul; Ascierto, Paolo A; Haanen, John; Espinosa, Enrique; Demidov, Lev; Garbe, Claus; Guida, Michele; Lorigan, Paul; Chiarion-Sileni, Vanna; Gogas, Helen; Maio, Michele; Fierro, Maria Teresa; Hoeller, Christoph; Terheyden, Patrick; Gutzmer, Ralf; Guren, Tormod K; Bafaloukos, Dimitrios; Rutkowski, Piotr; Plummer, Ruth; Waterston, Ashita; Kaatz, Martin; Mandala, Mario; Marquez-Rodas, Ivan; Muñoz-Couselo, Eva; Dummer, Reinhard; Grigoryeva, Elena; Young, Tina C; Schadendorf, Dirk (2019). Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 119:168-178.

Lebbe, Celeste; Garbe, Claus; Stratigos, Alexander J; Harwood, Catherine; Peris, Ketty; Marmol, Veronique Del; Malvehy, Josep; Zalaudek, Iris; Hoeller, Christoph; Dummer, Reinhard; Forsea, Ana Maria; Kandolf-Sekulovic, Lidija; Olah, Judith; Arenberger, Petr; Bylaite-Bucinskiene, Matilda; Vieira, Ricardo; Middleton, Mark; Levy, Antonin; Eggermont, Alexander M; Battistella, Maxime; Spano, Jean Philippe; Grob, Jean Jacques; Pages, Cecile; European Dermatology Forum (EDF), the European Association of De (2019). Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). European Journal of Cancer, 114:117-127.

Gutzmer, Ralf; Harrington, Kevin J; Hoeller, Christoph; Lebbé, Celeste; Malvehy, Josep; Öhrling, Katarina; Downey, Gerald; Dummer, Reinhard (2018). Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. European Journal of Dermatology, 28(6):736-749.

Grob, Jean Jacques; Schadendorf, Dirk; Lorigan, Paul; Ascierto, Paolo; Larkin, James; Nathan, Paul; Robert, Caroline; Hauschild, Axel; Weber, Jeffrey; Daud, Adil; Hamid, Omid; Dummer, Reinhard; Hansson, Johan; Hoeller, Christoph; Schachter, Jacob; Van Akkooi, Alexander C J; Garbe, Claus (2018). Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer, 91:168-170.

Dummer, Reinhard; Hoeller, Christoph; Gruter, Isabella Pezzani; Michielin, Olivier (2017). Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunology, Immunotherapy, 66(6):683-695.

Deken, Marcel A; Gadiot, Jules; Jordanova, Ekaterina S; Lacroix, Ruben; van Gool, Melissa; Kroon, Paula; Pineda, Cristina; Geukes Foppen, Marnix H; Scolyer, Richard; Song, Ji-Ying; Verbrugge, Inge; Hoeller, Christoph; Dummer, Reinhard; Haanen, John B A G; Long, Georgina V; Blank, Christian U (2016). Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology, 5(12):e1238557.

Mangana, Joanna; Cheng, Phil F; Schindler, Katja; Weide, Benjamin; Held, Ulrike; Frauchiger, Anna L; Romano, Emanuella; Kähler, Katharina C; Rozati, Sima; Rechsteiner, Markus; Moch, Holger; Michielin, Olivier; Garbe, Claus; Hauschild, Axel; Hoeller, Christoph; Dummer, Reinhard; Goldinger, Simone M (2015). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival? PLoS ONE, 10(10):e0139438.

Goldinger, Simone M; Zimmer, Lisa; Schulz, Carsten; Ugurel, Selma; Hoeller, Christoph; Kaehler, Katharina C; Schadendorf, Dirk; Hassel, Jessica C; Becker, Juergen; Hauschild, Axel; Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50(2):406-410.

This list was generated on Sun Sep 22 16:34:49 2019 CEST.